MYD88 and diffuse large B-cell lymphoma: The pre-clinical studies suggest that the silencing of the mutant MYD88 gene expression can be achieved by utilizing histone deacetylase inhibitors and that this epigenetic reprogramming exerts synergy with ibrutinib in DLBCL [56,57].